Search

everythinglearnresearchcommunity

for

Search:↓

Dermatologists give better information on pathology forms, hypersensitivity vasculitis is a common skin issue, misdiagnoses can occur, and various skin conditions are linked to loss of elastin or genetic factors.

Older age and related diseases increase COVID-19 risk, but anti-aging treatments might help.

Faulty inflammasome activation may lead to autoimmune skin diseases and could be a target for new treatments.

Deucravacitinib improves symptoms and reduces inflammation in Lichen Planopilaris.

Lifestyle changes can help manage androgenetic alopecia.

The hydrogel helps heal wounds without scars by releasing two drugs gradually.

Fenugreek seeds help with diabetes and cholesterol, while leaves fight microbes and dandruff.

Type-2 immunity may influence skin diseases and could be targeted for treatment.

Lichen planopilaris can occur with multiple autoimmune diseases.

RANK-RANKL signaling is essential for hair growth and skin health.

Some plant-based chemicals may help with hair growth, but more research is needed to confirm their effectiveness.

Alopecia Areata is an autoimmune disease causing hair loss, with no cure yet, but research may lead to new treatments.

Baseline severity and relapse history affect alopecia areata treatment and recurrence.

Different immune responses cause hair loss in scalp diseases, with unique patterns in scalp psoriasis possibly protecting against hair loss.

Individualized treatment and psychological support are crucial for alopecia.

Understanding gene expression in hair follicles can reveal insights into hair growth and disorders.

A patient with Alopecia Areata had complete hair regrowth after using the drug baricitinib.

Oxidative stress contributes to hair graying and loss as we age.

Ritlecitinib is approved in the USA and Japan for treating severe hair loss in people aged 12 and older.

Animal models have helped understand hair loss from alopecia areata and find new treatments.

New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.

Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.

Targeting abnormal lung fluid metabolism could reduce COVID-19 deaths and ventilator use.

Lymphocytes, especially CD8+ T cells, play a key role in causing alopecia areata, and targeting them may lead to new treatments.

Tofacitinib was effective in treating hair loss in two patients with alopecia universalis.

Prolactin may play a significant role in skin and hair health and could be a target for treating skin and hair disorders.

Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.

New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.

Women with PCOS have a higher risk of severe COVID-19 due to related health issues.

Consider benefits and risks of new alopecia treatments for safety.